← Back to Screener
Aardvark Therapeutics, Inc. Common Stock (AARD)
Price$5.65
Favorite Metrics
Price vs S&P 500 (26W)-76.58%
Price vs S&P 500 (4W)19.01%
Market Capitalization$114.10M
All Metrics
Book Value / Share (Quarterly)$4.89
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.49
Price vs S&P 500 (YTD)-64.29%
EPS (TTM)$-2.93
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-2.93
EPS (Annual)$-2.93
ROI (Annual)-54.01%
Cash / Share (Quarterly)$5.04
ROA (Last FY)-49.15%
EBITD / Share (TTM)$-3.20
Cash Flow / Share (Annual)$-2.49
P/B Ratio1.07x
P/B Ratio (Quarterly)2.68x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-5.16x
ROA (TTM)-41.51%
EPS Incl Extra (Annual)$-2.93
Current Ratio (Annual)10.61x
Quick Ratio (Quarterly)10.43x
3-Month Avg Trading Volume0.27M
52-Week Price Return-30.91%
Revenue / Employee (TTM)$0
52-Week High$17.94
EPS Excl Extra (Annual)$-2.93
26-Week Price Return-67.84%
Quick Ratio (Annual)10.43x
13-Week Price Return-65.09%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.61x
Enterprise Value$67.047
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.04
3-Month Return Std Dev141.89%
Net Income / Employee (TTM)$-2
ROE (Last FY)-54.01%
EPS Basic Excl Extra (Annual)$-2.93
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.93
ROI (TTM)-44.59%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-66.01%
Year-to-Date Return-60.15%
5-Day Price Return30.42%
EPS Normalized (Annual)$-2.93
Month-to-Date Return38.73%
EBITD / Share (Annual)$-3.19
EPS Basic Excl Extra (TTM)$-2.93
P/B Ratio (Annual)2.68x
Book Value / Share (Annual)$4.89
Price vs S&P 500 (13W)-67.95%
Beta4.02x
Revenue / Share (TTM)$0.00
ROE (TTM)-44.59%
52-Week Low$3.35
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.41
4.39
4.39
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AARDAardvark Therapeutics, Inc. Common Stock | — | — | — | — | $5.65 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target Bitter Taste Receptors (TAS2Rs) to treat metabolic and hunger-associated conditions. The company's lead candidate, ARD-101, is an oral gut-restricted TAS2R agonist currently in Phase 3 clinical trials for hyperphagia associated with Prader-Willi Syndrome.